Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Escalon MedicalESMC 34 Debt-to-EBITDA is 0.11 as of Mar. 2026. GuruFocus rates ESMC with a GF Score™ of 34/100 and a GF Value™ of $0.15 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 467 Medical Devices & Instruments companies, Escalon Medical ranks better than 69.38% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Escalon Medical's Debt-to-EBITDA or its related term are showing as below:
ESMC'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -9.03 Med: 0 Max: 118.13
Current: 0.53
During the past 13 years, the highest Debt-to-EBITDA Ratio of Escalon Medical was 118.13. The lowest was -9.03. And the median was 0.00.
ESMC's Debt-to-EBITDA is ranked better than 69.38% of 467
companies
in the Medical Devices & Instruments industry
Industry Median: 1.57
vs ESMC: 0.53
Escalon Medical (OTCPK:ESMC) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Escalon Medical Debt-to-EBITDA Related Terms
Escalon Medical Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Escalon Medical's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ESMC vs RBOT, NUWE, NUMD: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Escalon Medical's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Escalon Medical Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Escalon Medical's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Escalon Medical's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Escalon Medical (ESMC) has a Debt-to-EBITDA of 0.11 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Escalon Medical. According to the industry distribution chart, Escalon Medical ranks #143 out of 467 companies in the Medical Devices & Instruments industry, placing it in the top 30.6%.
Is Escalon Medical's Debt-to-EBITDA too high?
Escalon Medical's current Debt-to-EBITDA is 0.11. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.57. Escalon Medical's value of 0.11 is 93% below this industry median. Based on the distribution chart, Escalon Medical ranks #143 out of 467 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Escalon Medical has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Escalon Medical's Debt-to-EBITDA compare to RBOT and NUWE?
According to the Medical Devices & Instruments industry distribution chart, Escalon Medical ranks #143 out of 467 companies for Debt-to-EBITDA. This puts Escalon Medical in the upper half of its industry. The industry median Debt-to-EBITDA is 1.57. Escalon Medical's value of 0.11 is 93% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.57, based on 467 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Escalon Medical's current Debt-to-EBITDA of 0.11 is 93% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Escalon Medical. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Escalon Medical's current Debt-to-EBITDA is 0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Escalon Medical stock overvalued right now?
Based on GuruFocus' analysis, Escalon Medical (ESMC) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.15, compared to a current price of $0.20 — trading 33.3% above its estimated fair value. The current Debt-to-EBITDA is 0.11 and 93% below the Medical Devices & Instruments industry median of 1.57. Escalon Medical's overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Escalon Medical (ESMC), the current Debt-to-EBITDA is 0.11 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Escalon Medical (ESMC) Overvalued in 2026?
Based on GuruFocus' analysis, Escalon Medical stock appears to be overvalued.
The current stock price of $0.20 is trading 33.3% above its estimated GF Value™ of $0.15.
GuruFocus considers Escalon Medical to be Significantly Overvalued.
Key valuation signals for ESMC:
Debt-to-EBITDA: 0.11
GF Value™: $0.15 vs. price of $0.20 (33.3% above fair value)
Industry Position: 93% below the Medical Devices & Instruments median (#143 of 467)
No single metric tells the full story. See the ESMC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Escalon Medical Corp operates in the healthcare market, specializing in the development, manufacture, marketing, and distribution of medical devices and pharmaceuticals in the area of ophthalmology. Its products are A-Scans, B-Scans, UBM, Pachymeters, Ispan Intraocular Gases, Surgical Packs, Viscous Fluid Transfer Systems, and AXIS Image Management. Substantial revenue is generated from the domestic sales of products.
34GF Score
Get the complete analysis for ESMC
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ESMC has been successfully added to your 
